fbpx
X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:
Friday, September 24, 2021

Pacific Biosciences Grants Equity Incentive Award to New Employee

MENLO PARK, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock, and restricted stock units (“RSUs”) covering 50,000 shares of Pacific Biosciences common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”) effective on September 20, 2021. The 2020 Inducement Plan is used exclusively to grant…

Read More »

Monday, September 20, 2021

Pacific Biosciences Closes Acquisition of Omniome and Establishes San Diego Presence

Omniome’s high accuracy short-read sequencing platform expected to significantly expand PacBio’s market opportunity Acquisition expected to accelerate the adoption of SMRT Sequencing, PacBio’s leading long-read sequencing platform PacBio also closes $300 million PIPE financing in support of transaction MENLO PARK, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB)(“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, long-read sequencing platforms, and Omniome, a San Diego-based biotechnology company developing a proprietary and highly differentiated short-read sequencing platform capable of delivering increased sequencing accuracy, announced today the companies have closed the transaction under which Pacific Biosciences acquired Omniome. With…

Read More »

Friday, September 3, 2021

Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conferences

MENLO PARK, Calif., Sept. 03, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conferences: Wells Fargo Virtual Healthcare Conference on September 10, 2021, Fireside Chat at 12:40 pm Eastern Time (9:40 am Pacific Time) Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, Fireside Chat at 1:15 pm Eastern Time (10:15 am Pacific Time) 2021 Cantor Virtual Global Healthcare Conference on September 28, 2021, Fireside Chat at 2:40 pm Eastern Time (11:40 am Pacific Time) The live webcasts can be accessed at the…

Read More »

Monday, August 9, 2021

Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conference

MENLO PARK, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conference: UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2021, Panel Discussion at 4:00 pm Eastern Time (1:00 pm Pacific Time) The live webcasts can be accessed at the company’s investors page at investor.pacificbiosciences.com. The replays will be available for at least 30 days following the presentation. About Pacific Biosciences Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments…

Read More »

Tuesday, August 3, 2021

Pacific Biosciences of California, Inc. Announces Second Quarter 2021 Financial Results

MENLO PARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2021. Record second quarter revenue reflects continued quarter-over-quarter growth Revenue for the second quarter of 2021 was $30.6 million, representing an 79% increase compared with $17.1 million for the second quarter of 2020. The Company placed 38 Sequel II/IIe systems during the second quarter of 2021 compared to 23 Sequel II systems placed in the second quarter of 2020 and 41 Sequel II/IIe systems placed during the first quarter of 2021, bringing the total…

Read More »

Tuesday, August 3, 2021

Pacific Biosciences Acquires Circulomics – A Leading High Molecular Weight DNA Extraction Company

Technology Will Enable Continued End-to-End Automated Workflow Development MENLO PARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, long-read sequencing platforms, announced today that it acquired Circulomics Inc. (“Circulomics”), a Maryland-based biotechnology company focused on delivering highly differentiated sample prep products that enable genomic workflows. Scientists recognize Circulomics as a leader in extracting high quality, high molecular weight (HMW) DNA from almost any sample type. These products are commonly used for long read applications across a diverse set of markets including, human biomedical research, plant…

Read More »

Wednesday, July 28, 2021

Pacific Biosciences Grants Equity Incentive Award to New Employee

MENLO PARK, Calif., July 28, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted restricted stock units (“RSUs”) covering 29,500 shares of Pacific Biosciences common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”) effective on July 22, 2021 (the “Effective Date”). The 2020 Inducement Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee…

Read More »

Tuesday, July 20, 2021

Pacific Biosciences and Invitae Announce Intent to Expand Collaboration

Collaboration to develop production-scale HiFi Sequencing platformexpected to Include technology from Omniome, Inc. Combining both highly accurate long and short read sequencing technologies expected to provide deeper clinical insights and lower the overall cost of analysis MENLO PARK, Calif., July 20, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB)(“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, long-read sequencing platforms, and Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced an intent to expand their multi-year collaboration to develop a production-scale high-throughput HiFi sequencing platform to include the sequencing technology developed by Omniome, Inc. The…

Read More »

Tuesday, July 20, 2021

Pacific Biosciences Signs Definitive Agreement to Acquire Omniome

Combination aims to transform the genomics landscape and deliver a differentiated product offering into high growth clinical markets Brings together Omniome’s high accuracy short-read sequencing platform, with PacBio’s market leading, high accuracy long-read solutions Transaction supported by concurrent $300 million PIPE financing from premier life science investors MENLO PARK, Calif. and SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, long-read sequencing platforms, announced today that it has signed a definitive merger agreement under which it will acquire Omniome, a San Diego-based company developing a…

Read More »

Monday, July 19, 2021

Pacific Biosciences of California, Inc. Second Quarter 2021 Financial Results Call

MENLO PARK, Calif., July 19, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its second quarter 2021 financial results on Tuesday, August 3, 2021, at 4:30pm Eastern Time. The call will be webcast and may be accessed at Pacific Biosciences’ website at: https://investor.pacificbiosciences.com/. Date: Tuesday, August 3, 2021 Time: 4:30pm ET Listen via Internet: https://investor.pacificbiosciences.com/ Toll-free: 888.366.7247 International: 707.287.9330 Conference ID: 6914707 Replay: https://investor.pacificbiosciences.com About Pacific Biosciences Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based…

Read More »

Wednesday, June 23, 2021

Pacific Biosciences and Rady Children’s Institute for Genomic Medicine Announce its First Research Collaboration for Whole Genome Sequencing

HiFi Sequencing will be used on a cohort of rare disease cases with the aim to identify numerous variants, both small and structural, that are not readily detectable by short-read sequencing MENLO PARK, Calif., June 23, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB)(“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, long-read sequencing platforms, and Rady Children’s Institute for Genomic Medicine (RCIGM), a mission-driven, non-profit seeking to save lives and improve outcomes for patients, clinicians and families, shared today that they are collaborating on a study which aims to identify potential disease-causing genetic variants and increase…

Read More »

Friday, June 11, 2021

Pacific Biosciences Grants Equity Incentive Award to New Employee

MENLO PARK, Calif., June 11, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 80,000 shares of Pacific Biosciences common stock, and restricted stock units (“RSUs”) covering 40,000 shares of Pacific Biosciences common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”) effective on June 7, 2021. The 2020 Inducement Plan is used exclusively to grant…

Read More »

Monday, June 7, 2021

Pacific Biosciences Welcomes Neil Ward to Its Leadership Team as Vice President and General Manager for Europe, Middle East, and Africa

Industry Veteran Will Lead PacBio’s Commercial Footprint Across the Region MENLO PARK, Calif., June 08, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today welcomed Neil Ward to the new role of Vice President and General Manager for the company’s Europe, Middle East, and Africa (EMEA) region to expand and develop the team and infrastructure to capitalize on the immense potential for genomics in this area of the world. Neil is a genomics industry veteran with more than two decades of global experience. He most recently served as Senior…

Read More »

Friday, May 21, 2021

Pacific Biosciences Grants Equity Incentive Award to New Employee

MENLO PARK, Calif., May 21, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 240,000 shares of Pacific Biosciences common stock and restricted stock units (“RSUs”) covering 130,000 shares of Pacific Biosciences common stock to two recently hired employees under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”) effective on May 17, 2021. The 2020 Inducement Plan is…

Read More »

Monday, May 17, 2021

Pacific Biosciences Further Expands Leadership Team with Appointment of Dr. Catherine Ball to Newly Created Position of Senior Vice President of Research

Kathleen Lynch has joined as Head of Global Government Affairs and Communications and Michele Farmer has joined as Chief Accounting Officer MENLO PARK, Calif., May 17, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced the appointment of three new hires to its growing team. Dr. Catherine Ball joins the company as Senior Vice President of Research, Kathleen Lynch joins as Head of Global Government Affairs and Corporate Communications, and Michele Farmer joins as Chief Accounting Officer. Dr. Ball is a product of the California education system having completed…

Read More »

1 2 3 18

Subscribe for blog updates:

Archives

Stay
Current

Visit our blog »